Single-Use Bioreactor Patents: Top Companies & Filing Trends 2026
Single-Use Bioreactor Vessel Design Patents: Who Holds the Ground
42.9% of all 734 records sit with just five assignees — vessel geometry and port-layout claims are concentrated at the top, not spread thin. Annual filings rose from 39 in 2017 to a peak of 101 in 2023, then dropped to 22 by 2024 — a -41% move from 2021's 37. Publication lags filing by roughly 18 months, so 2025 and 2026 figures are undercounts still filling in, not evidence of a real slowdown.
- 1GENZYME CORP103
- 2REGENERON PHARMACEUTICALS INC90
- 3GLOBAL LIFE SCIENCES SOLUTIONS USA LLC44
- 4PROTALIX43
- 5LONZA AG35
See the full single-use bioreactor vessel design analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on single-use bioreactor vessel design patents
Who holds the most patents on single-use bioreactor vessel design?
The assignee ranking shows a clearly concentrated top: the leading assignee holds 103 records, and the top five assignees combined account for 42.9% of all 734 records in scope. That concentration extends to the top 10, which together hold 61.9% of all records. Below that group the ranking runs to 100 companies with a long tail of firms holding far fewer filings each, so a freedom-to-operate review should prioritise the concentrated leaders before working down the tail.
Is single-use bioreactor patent filing activity growing or slowing down?
Filing activity grew from 39 records in 2017 to a peak of 101 in 2023, then declined to 22 by 2024, a -41% move from 2021’s 37 records. However, publication lags filing by roughly 18 months, so the 2025 and 2026 figures in any trend chart are undercounts still filling in. Treat 2024 as the most recent year that can be read as a complete data point, and avoid concluding the field is slowing based on the two most recent years alone.
What technology areas overlap most with bioreactor vessel design claims?
Beyond the core bioreactor classification, which by definition covers 100% of the 734 records, the next most common overlapping class is C12N microorganism and genetic engineering at 23.3% of records, followed by C07K peptide and protein claims at 10.1% and C12P fermentation claims at 9.7%. Mixing and stirring apparatus (B01F) and separation processes (B01D) trail well behind at 9.4% and 2.9% respectively. Since a single record can carry several IPC classes, these shares add up to more than 100% and should not be read as a breakdown of the whole.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Single-Use Bioreactor Vessel Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.